Get the Stockscreener App
0.742
27.25%
-0.278
Pre-market:
.69
-0.052
-7.01%
Transcode Therapeutics Inc stock is traded at $0.742, with a volume of 10.31M.
It is down -27.25% in the last 24 hours and down -93.04% over the past month.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
See More
Previous Close:
$1.02
Open:
$0.9127
24h Volume:
10.31M
Relative Volume:
5.14
Market Cap:
$516.62K
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.00279
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
-56.09%
1M Performance:
-93.04%
6M Performance:
-91.32%
1Y Performance:
-96.56%
1-Day Range:
$0.74
$0.9399
1-Week Range:
$0.74
$1.68
52-Week Range:
$0.74
$66.33
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
0.742 | 516.62K | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga India
TransCode Therapeutics Advances Phase I Trial Of RNA Cancer Therapy - Nasdaq
Transcode Therapeutics’ fourth cohort in Phase 1/2 cancer trial approved - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
TransCode Therapeutics Says Safety Review Committee Approves Opening of Fourth Group in Phase 1 Trial to Treat Metastatic Cancers - Marketscreener.com
TransCode's Cancer Drug Shows Perfect Safety Record as Trial Expands to Higher Doses - StockTitan
Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews
Transcode Therapeutics stock hits 52-week low at $1.7 By Investing.com - Investing.com Canada
Transcode Therapeutics stock hits 52-week low at $1.7 - Investing.com
Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews
The Significance of Moving Averages in TransCode Therapeutics Inc Inc. (RNAZ) Price Performance - The InvestChronicle
Transcode Therapeutics stock hits 52-week low at $2.62 By Investing.com - Investing.com South Africa
Transcode Therapeutics stock hits 52-week low at $2.62 - Investing.com
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.37% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.37% - Investing.com
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.37% - Investing.com UK
TransCode Therapeutics, Inc. Announces Results of Special Meeting - Yahoo Finance
Stock market news: China SXT Pharmaceuticals -92.51%, TransCode Therapeutics -37.91% among biggest losers during midday trading - Business Upturn
Nasdaq Dips 1.5%; Home Depot Issues Weak Forecast - Benzinga India
TransCode Shareholders Green-Light Warrant Changes: What This Means for RNAZ's Financial Future - StockTitan
Learn to Evaluate (RNAZ) using the Charts - Stock Traders Daily
TransCode reports positive phase 1 trial progress for cancer therapy - MSN
vTv Therapeutics (NASDAQ:VTVT) Earns Sell Rating from Analysts at StockNews.com - Defense World
(RNAZ) Technical Data - Stock Traders Daily
Clinical Trials News Live Feed - StockTitan
RNAZ’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
The -45.19% Simple Moving Average of TransCode Therapeutics Inc’s (RNAZ) Stock in the Past 200 Days - The News Heater
The Impact of Market Fluctuations on ChargePoint Holdings Inc’s (CHPT) Stock - The News Heater
Market Analysts see Helmerich & Payne, Inc [HP] falling to $39. Time to buy? - The DBT News
Wag Group Co [PET] Revenue clocked in at $76.75 million, up 36.38% YTD: What’s Next? - The DBT News
Wall Street Analyst Reiterated Gamestop Corporation [GME]. What else is Wall St. saying - The DBT News
Shoals Technologies Group Inc [SHLS] Stock trading around $4.60 per share: What’s Next? - The DBT News
Ensysce Biosciences (NASDAQ:ENSC) Stock Quotes, Forecast and News Summary - Benzinga
Cronos Group Inc [CRON] fell 0.00% so far this year. What now? - The DBT News
Northern Dynasty Minerals Ltd [NAK] is 26.40% higher this YTD. Is it still time to buy? - The DBT News
For Coupang Inc [CPNG], Analyst sees a rise to $30. What next? - The DBT News
Market Analysts see BBB Foods Inc [TBBB] gaining to $32. Time to buy? - The DBT News
why Borr Drilling Ltd [BORR] is a Good Choice for Investors After New Price Target of $5.23 - The DBT News
American Superconductor Corp [AMSC] Stock trading around $34.24 per share: What’s Next? - The DBT News
Callan JMB Inc [CJMB] gain 54.15% so far this year. What now? - The DBT News
Wall Street Analyst Resumed Equillium Inc [EQ]. What else is Wall St. saying - The DBT News
why Silexion Therapeutics Corp [SLXN] is a Good Choice for Investors After New Price Target of $9.00 - The DBT News
SNDL Inc [SNDL] Is Currently 3.76 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
Envista Holdings Corp [NVST] moved up 5.93: Why It’s Important - The DBT News
2 Top Fintech Stocks to Buy in February - The Globe and Mail
Wall Street Analyst Resumed Lilly[Eli] & Co [LLY]. What else is Wall St. saying - The DBT News
Health In Tech Inc [HIT] Revenue clocked in at $19.80 million, down -0.84% YTD: What’s Next? - The DBT News
AEON Biopharma Inc [AEON] Stock trading around $0.14 per share: What’s Next? - The DBT News
Stocks of TransCode Therapeutics Inc (RNAZ) are poised to climb above their peers - SETE News
TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright - Armenian Reporter
Insider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Purchases $103,200.00 in Stock - Armenian Reporter
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):